MedTrace Logo

CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide

NCT00514345 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2013-08-12

No results posted yet for this study

Summary

RATIONALE: Studying the genes expressed in samples of blood from young patients with cancer treated with ifosfamide may help doctors identify risk factors for kidney damage.

PURPOSE: This clinical trial is looking at the CYP3A5 gene to see if having the gene may be a risk factor for kidney damage in young patients with cancer treated with ifosfamide.

Conditions

  • Chemotherapeutic Agent Toxicity
  • Sarcoma
  • Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

GENETIC

gene expression analysis

GENETIC

polymorphism analysis

PROCEDURE

management of therapy complications

Sponsors & Collaborators

  • Children's Cancer and Leukaemia Group

    lead OTHER

Principal Investigators

  • Gareth Veal · University of Newcastle Upon-Tyne

Eligibility

Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31

Countries

  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00514345 on ClinicalTrials.gov